Skip to main content
Triangle logo TriangleGet started

Cytarabine (NCT00801489)

Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome: a one-minute explainerNCT008014891 min

Cytarabine trial for Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11 (NCT00801489). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with newly diagnosed AML or high-risk MDS carrying t(8;21), inv(16) or t(16;16). One prior induction course is allowed when these chromosome findings were initially missed.

The idea: combine fludarabine, cytarabine and gemtuzumab ozogamicin with filgrastim support. Gemtuzumab delivers a cell-killing payload to CD33-bearing cells. Later treatment depends on response: selected patients receive idarubicin or modified treatment with decitabine. Researchers assess remission and toxicity and track molecular evidence of leukemia. Filgrastim supports blood-cell recovery.

This phase 2 study plans 270 patients. Jayastu Senapati leads MD Anderson in Houston.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.